BioSpace News Archive

Novavax, Inc. and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for NVX-CoV2373.

Increasing need to lower healthcare-associated infections, growing use of antiseptics agents, and rising number of surgeries globally are some key factors expected to drive market growth.

Watson Guide I.P. LLC announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,173,016 which is directed to methods and apparatus related to full arch implant guided surgery through the use of a fixation base as a mounting jig for a plurality of guides and installation of multi-tooth dental restorations.

Increasing focus on personal appearance and grooming, technological advances in cosmetic surgical procedures, and rising preference for non-invasive cosmetic treatments are some of the key factors expected to drive market revenue growth over the upcoming years.

Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company “Block” signed an agreement on the implementation of the construction of a scientific and pharmaceutical complex in the territory of the Tashkent Pharma Park in Uzbekistan.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from the ongoing clinical study of its novel anti-FcyRIIB antibody BI-1206 in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with solid tumors.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in children ages 4 to less than 12 years.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

CooperCompanies announced it has completed the previously announced definitive purchase agreement to acquire Generate Life Sciences, a leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage, for a purchase price of approximately $1.6 billion.

Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research.